130 related articles for article (PubMed ID: 33172777)
1. Three Primary Tumors Including EGFR-mutated Non-Small Cell Lung Cancer as First Presentation in Patient With Li-Fraumeni Syndrome.
Gower A; Kim J; Spector K; Menashe D; Vail E; Natale R
Clin Lung Cancer; 2021 Jan; 22(1):e116-e121. PubMed ID: 33172777
[No Abstract] [Full Text] [Related]
2. Lung adenocarcinoma in a patient with Li-Fraumeni syndrome bearing a novel germ-line mutation, TP53R333Vfs*12.
Takahashi S; Shimazu K; Kodama K; Fukuda K; Yoshida T; Taguchi D; Takahashi T; Nanjyo H; Shibata H
Jpn J Clin Oncol; 2020 Sep; 50(10):1214-1217. PubMed ID: 32577752
[TBL] [Abstract][Full Text] [Related]
3. EFGR-mutant lung adenocarcinoma and Li-Fraumeni syndrome: report of two cases and review of the literature.
Ricordel C; Labalette-Tiercin M; Lespagnol A; Kerjouan M; Dugast C; Mosser J; Desrues B; Léna H
Lung Cancer; 2015 Jan; 87(1):80-4. PubMed ID: 25433984
[TBL] [Abstract][Full Text] [Related]
4. High Prevalence of EGFR Mutations in Lung Adenocarcinomas From Brazilian Patients Harboring the TP53 p.R337H Variant.
Barbosa MVR; Cordeiro de Lima VC; Formiga MN; Andrade de Paula CA; Torrezan GT; Carraro DM
Clin Lung Cancer; 2020 Mar; 21(2):e37-e44. PubMed ID: 31889631
[No Abstract] [Full Text] [Related]
5. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
6. EGFR-mutated lung cancer in Li-Fraumeni syndrome.
Michalarea V; Calcasola M; Cane P; Tobal K; Izatt L; Spicer J
Lung Cancer; 2014 Sep; 85(3):485-7. PubMed ID: 25047674
[TBL] [Abstract][Full Text] [Related]
7. High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome.
Mezquita L; Jové M; Nadal E; Kfoury M; Morán T; Ricordel C; Dhooge M; Tlemsani C; Léna H; Teulé A; Álvarez JV; Raimbourg J; Hiret S; Lacroix L; Menéndez M; Saldaña J; Brunet J; Lianes P; Coupier I; Auclin E; Recondo G; Friboulet L; Adam J; Green E; Planchard D; Frébourg T; Capellà G; Rouleau E; Lázaro C; Caron O; Besse B
J Thorac Oncol; 2020 Jul; 15(7):1232-1239. PubMed ID: 32179180
[TBL] [Abstract][Full Text] [Related]
8. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
9. The Clinical and Molecular Profile of Lung Cancer Patients Harboring the
Lopes CDH; Antonacio FF; Moraes PMG; Asprino PF; Galante PAF; Jardim DL; de Macedo MP; Sandoval RL; Katz A; de Castro G; Achatz MI
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894716
[TBL] [Abstract][Full Text] [Related]
10. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
11. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.
Giacomazzi J; Selistre S; Duarte J; Ribeiro JP; Vieira PJ; de Souza Macedo G; Rossi C; Czepielewski M; Netto CB; Hainaut P; Ashton-Prolla P
BMC Cancer; 2013 Apr; 13():187. PubMed ID: 23570263
[TBL] [Abstract][Full Text] [Related]
12. Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial.
Caron O; Frebourg T; Benusiglio PR; Foulon S; Brugières L
JAMA Oncol; 2017 Dec; 3(12):1736-1737. PubMed ID: 28772306
[TBL] [Abstract][Full Text] [Related]
13. The first pancreatic neuroendocrine tumor in Li-Fraumeni syndrome: a case report.
Aversa JG; De Abreu FB; Yano S; Xi L; Hadley DW; Manoli I; Raffeld M; Sadowski SM; Nilubol N
BMC Cancer; 2020 Mar; 20(1):256. PubMed ID: 32228502
[TBL] [Abstract][Full Text] [Related]
14. Brain tumors in Li-Fraumeni syndrome: a commentary and a case of a gliosarcoma patient.
Guidi M; Giunti L; Lucchesi M; Scoccianti S; Giglio S; Favre C; Oliveri G; Sardi I
Future Oncol; 2017 Jan; 13(1):9-12. PubMed ID: 27523101
[No Abstract] [Full Text] [Related]
15. High frequency of de novo mutations in Li-Fraumeni syndrome.
Gonzalez KD; Buzin CH; Noltner KA; Gu D; Li W; Malkin D; Sommer SS
J Med Genet; 2009 Oct; 46(10):689-93. PubMed ID: 19556618
[TBL] [Abstract][Full Text] [Related]
16. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
17. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
18. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
19. Germline TP53 mutations and Li-Fraumeni syndrome.
Varley JM
Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
Jiao XD; Qin BD; You P; Cai J; Zang YS
Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
